Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
Immutep (NASDAQ: IMMP) announces upcoming presentation of new Phase IIb data from TACTI-003 trial's Cohort B at ESMO Immuno-Oncology Congress 2024. The study focuses on first-line recurrent/metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression (CPS <1), evaluating the combination of eftilagimod alpha and pembrolizumab. Dr. Martin Forster from UCL Cancer Institute will present the findings on December 12, 2024, in Geneva, Switzerland. The abstract will be available on December 5, with the complete poster released on Immutep's website after the presentation.
Immutep (NASDAQ: IMMP) annuncia la prossima presentazione di nuovi dati della Fase IIb del trial TACTI-003, relativo al Gruppo B, al Congresso ESMO di Immuno-Oncologia 2024. Lo studio si concentra su pazienti con carcinoma squamoso a cellule della testa e del collo recidivante/metastatico con espressione negativa di PD-L1 (CPS <1), valutando la combinazione di eftilagimod alpha e pembrolizumab. Il Dr. Martin Forster dell'UCL Cancer Institute presenterà i risultati il 12 dicembre 2024 a Ginevra, Svizzera. L'abstract sarà disponibile il 5 dicembre, con il poster completo pubblicato sul sito di Immutep dopo la presentazione.
Immutep (NASDAQ: IMMP) anuncia la próxima presentación de nuevos datos de la Fase IIb del ensayo TACTI-003, Cohorte B, en el Congreso ESMO de Inmuno-Oncología 2024. El estudio se centra en pacientes con carcinoma de células escamosas recurrente/metastásico de cabeza y cuello con expresión negativa de PD-L1 (CPS <1), evaluando la combinación de eftilagimod alfa y pembrolizumab. El Dr. Martin Forster del UCL Cancer Institute presentará los resultados el 12 de diciembre de 2024 en Ginebra, Suiza. El resumen estará disponible el 5 de diciembre, con el póster completo publicado en el sitio web de Immutep después de la presentación.
Immutep (NASDAQ: IMMP)는 ESMO 면역 종양학 Congress 2024에서 TACTI-003 시험의 Cohort B에서 새로운 2b상 데이터 발표를 예고합니다. 이 연구는 PD-L1 발현이 부정적인 1차 재발/전이성 두경부 편평세포암 환자(CPS <1)에 초점을 맞추고, eftilagimod 알파와 pembrolizumab의 조합을 평가합니다. UCL Cancer Institute의 Martin Forster 박사가 2024년 12월 12일 스위스 제네바에서 연구 결과를 발표할 예정입니다. 초록은 12월 5일에 제공되며, 전체 포스터는 발표 이후 Immutep의 웹사이트에 게시될 것입니다.
Immutep (NASDAQ: IMMP) annonce la prochaine présentation de nouvelles données de l'étude de Phase IIb de l'essai TACTI-003, Cohorte B, lors du Congrès ESMO d'Immuno-Oncologie 2024. L'étude se concentre sur des patients atteints de carcinome spinocellulaire de la tête et du cou récurrent/métastatique avec une expression négative de PD-L1 (CPS <1), évaluant la combinaison d'eftilagimod alpha et de pembrolizumab. Le Dr. Martin Forster de l'UCL Cancer Institute présentera les résultats le 12 décembre 2024 à Genève, en Suisse. Le résumé sera disponible le 5 décembre, avec le poster complet publié sur le site d'Immutep après la présentation.
Immutep (NASDAQ: IMMP) kündigt die bevorstehende Präsentation neuer Phase-IIb-Daten aus der Kohorte B der TACTI-003-Studie auf dem ESMO Immuno-Oncology Congress 2024 an. Die Studie konzentriert sich auf Patienten mit rezidivierendem/metastasiertem Plattenepithelkarzinom des Kopfes und Halses mit negativer PD-L1-Expression (CPS <1) und bewertet die Kombination von eftilagimod alpha und pembrolizumab. Dr. Martin Forster vom UCL Cancer Institute wird die Ergebnisse am 12. Dezember 2024 in Genf, Schweiz, präsentieren. Die Zusammenfassung wird am 5. Dezember verfügbar sein, das komplette Poster wird nach der Präsentation auf der Website von Immutep veröffentlicht.
- Phase IIb trial data selected for presentation at major oncology conference (ESMO I-O)
- None.
Media Release
SYDNEY, AUSTRALIA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it will present new data from Cohort B of the TACTI-003 Phase IIb trial in first line recurrent/metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression (CPS <1) at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2024 taking place 11-13 December in Geneva, Switzerland.
Presentation details:
| Title: | TACTI-003 Cohort B: Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma with CPS <1 |
| Presenter: | Martin Forster, M.D., Ph.D., University College London (UCL) Cancer Institute and UCL Hospital NHS Foundation, London, UK |
| Presentation Number: | 152P |
| Date and Time: | Thursday, 12 December 2024 at 12:30 – 13:30PM CET |
Abstracts will be made available on the ESMO I-O website on 5 December 2024 at 00:05 CET. The poster containing new data, not in the abstract, will be available on the Posters & Publications section of Immutep’s website after its presentation on 12 December 2024.
About Immutep
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Sodali & Co
+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
FAQ
When will Immutep (IMMP) present its TACTI-003 Phase IIb trial data at ESMO I-O 2024?
What is the focus of Immutep's (IMMP) TACTI-003 Phase IIb trial presentation?
When will the TACTI-003 trial abstracts be available for Immutep (IMMP)?
